- Series: Jones and Bartlett Series in Oncology
- Paperback: 480 pages
- Publisher: Jones and Bartlett Publishers, Inc.; 2 Sub edition (July 25, 2003)
- Language: English
- ISBN-10: 0763722545
- ISBN-13: 978-0763722548
- Product Dimensions: 6.1 x 1.2 x 9 inches
- Shipping Weight: 1.7 pounds
- Average Customer Review: 1.0 out of 5 stars See all reviews (1 customer review)
- Amazon Best Sellers Rank: #10,713,369 in Books (See Top 100 in Books)
Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
To get the free app, enter your mobile phone number.
American Cancer Society Consumer's Guide to Cancer Drugs, Second Edition (Jones and Bartlett Series in Oncology) 2 Sub Edition
Use the Amazon App to scan ISBNs and compare prices.
See the Best Books of 2017 So Far
Looking for something great to read? Browse our editors' picks for the best books of the year so far in fiction, nonfiction, mysteries, children's books, and much more.
Browse award-winning titles. See more
If you are a seller for this product, would you like to suggest updates through seller support?
Top customer reviews
The Role of the ACS in the War Against Cancer
The verdict is unassailable. The American Cancer Society bears a major responsibility for losing the winnable war against cancer.
The launching of the 1971 War Against Cancer provided the ACS with a well-exploited opportunity to pursue it own myopic and self-interested agenda. Its strategies remain based on two lies -- that there has been dramatic progress in the treatment and cure of cancer, and that any increase in the incidence and mortality of cancer is due to aging of the population and smoking while denying any significant role for involuntary exposures to industrial carcinogens in air, water, consumer products and the workplace.
Most of the funds raised by ACS go to pay overhead, salaries, fringe benefits, and travel expenses of its national executives in Atlanta. They also go to pay Chief Executive Officers, who earn six-figure salaries in several states, and the hundreds of other employees who work out of some 3,000 regional offices nationwide. The typical ACS affiliate, which helps raise the money for the national office, spends more than 52 percent of its budget on salaries, pensions, fringe benefits, and overhead for its own employees.
Salaries and overhead for most ACS affiliates also exceeded 50 percent, although most direct community services are handled by unpaid volunteers. DiLorenzo summed up his findings by emphasizing the hoarding of funds by the ACS.
"Most contributors believe their donations are being used to fight cancer, not to accumulate financial reserves. More progress in the war against cancer would be made if they would divest some of their real estate holdings and use the proceeds -- as well as a portion of their cash reserves -- to provide more cancer services."
Aside from high salaries and overhead, most of what is left of the ACS budget goes to basic research and research into profitable, patented cancer drugs.
The current budget of the ACS is $380 million and its cash reserves approach one billion dollars. Yet its aggressive fund-raising campaign continues to plead poverty, and lament the lack of available money for cancer research, while ignoring efforts to prevent cancer by phasing out avoidable exposures to environmental and occupational carcinogens.
Meanwhile, the ACS is silent about its intricate relationships with the wealthy cancer drug industry and chemical industries.
Read more....... [...]